SSG
MYGN icon

Summit Securities Group’s Myriad Genetics MYGN Stock Holding History

Summit Securities Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-181
Closed -$1.6K – 1301
2025
Q1 		$1.6K Buy
+181
New +$2.17K ﹤0.01% 678
2024
Q1 		– Sell
-100
Closed -$2K – 752
2023
Q4 		$2K Buy
+100
New +$1.73K ﹤0.01% 622
2013
Q3 		– Sell
-400
Closed -$11K – 513
2013
Q2 		$11K Buy
+400
New +$11.6K 0.01% 306

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Summit Securities Group's MYGN Position: Q2 2025 in Review

Summit Securities Group sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 181 shares — an estimated $1.6K sold.

Summit Securities Group first reported a position in MYGN in Q2 2013 and held it in 3 quarters. The position peaked at $11K in Q2 2013. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Summit Securities Group reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 181 Myriad Genetics shares in Q2 2025, an estimated $1.6K.
  • Summit Securities Group first reported a position in Myriad Genetics in Q2 2013 and held it in 3 quarters.
  • Summit Securities Group's Myriad Genetics position peaked at $11K in Q2 2013.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.